Karoline Anisdahl

6PUBLICATIONS
16CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Regenerative medicine (incl. stem cells)AllergyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 28, 2026
Therapeutic drug monitoring in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab: insights from a prospective real-world study.

Camilla Bergsmark, Vendel A Kristensen, Maren B Sjåmo

|Mar 28, 2024
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.

Thea H Wiken, Marte L Høivik, Karoline Anisdahl

|Feb 17, 2023
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.

Thea H Wiken, Marte L Høivik, Lydia Buer

|Feb 15, 2023
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.

Kristin Kaasen Jørgensen, Marte Lie Høivik, Adity Chopra

|Jul 28, 2022
Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.

Mirabella Zhao, Sandre Lirhus, Mikael Lördal

|Jul 29, 2021
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.

Karoline Anisdahl, Sandre Svatun Lirhus, Asle W Medhus

Pageof 1

Frequent Collaborators

4 joint publications

Asle W Medhus

4 joint publications

Marte Lie Høivik

2 joint publications

Bjørn Moum

2 joint publications

Lydia Buer